Investigating and Characterizing the Immune Response to Prostate Cancer
Prostate Cancer
About this trial
This is an interventional basic science trial for Prostate Cancer focused on measuring Cryotherapy, Radiation, Prostatectomy, Immune Response
Eligibility Criteria
Inclusion Criteria:
- Patient is willing and able to freely sign informed consent to enroll in the study.
- Histologically proven Prostate Carcinoma.
- Undergoing total cryotherapy, focal cryotherapy, Cyberknife SBRT or radical prostatectomy for prostate cancer treatment.
Exclusion Criteria:
- Has previously had a radical prostatectomy for prostate cancer.
- Has previously received cryotherapy for prostate cancer.
- Previous treatment with chemotherapy within the past 6 months.
- Previous treatment with radiation within the past 18 months.
- Has evidence of metastatic disease.
- Has a current or history within the past 6 months of alcohol and/or substance abuse which would impair participation in the study.
- Has a major medical disorder (i.e. uncontrolled diabetes, significant hepatic, renal or hematological disorders, recent stroke or myocardial infarction), in the opinion of the urologist, is an illness or complication which is not consistent with the protocol requirements.
- Is not willing to undergo the necessary follow-up for the trial period.
- Has known immunologic disease, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
Sites / Locations
- NYU Winthrop Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Total Cyrotherapy of the Prostate
Focal Cryotherapy of the Prostate
Cyberknife SBRT of the Prostate
Radical Prostatectomy
Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)